{"id":55187,"date":"2023-03-25T14:03:04","date_gmt":"2023-03-25T13:03:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/"},"modified":"2023-03-25T14:03:04","modified_gmt":"2023-03-25T13:03:04","slug":"immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/","title":{"rendered":"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting"},"content":{"rendered":"
\n

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc.<\/a> (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in Tampa, Florida.\n<\/p>\n

<\/a><\/p>\n

\nOral Presentation Details
\n
<\/b>Title: Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Evaluation of Sequence of Therapy on Anti-Tumor Activity in the SORAYA Study
\n
Session: Scientific Plenary I: Progress: Therapeutics Innovations
\n
Session Date: Saturday, March 25, 2023
\n
Session Time: 9:00 am to 10:30 am ET\n<\/p>\n

\nAdditional information can be found at www.sgo.org<\/a>.\n<\/p>\n

\nABOUT IMMUNOGEN
\n
<\/b>ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW\u2122.\n<\/p>\n

\nLearn more about who we are, what we do, and how we do it at www.immunogen.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nINVESTOR RELATIONS<\/b>
ImmunoGen
\n
Anabel Chan
\n
781-895-0600
\n
anabel.chan@immunogen.com<\/a><\/p>\n

MEDIA<\/b>
ImmunoGen
\n
Courtney O’Konek
\n
781-895-0600
\n
courtney.okonek@immunogen.com<\/a><\/p>\n

OR<\/p>\n

FTI Consulting
\n
Robert Stanislaro
\n
212-850-5657
\n
robert.stanislaro@fticonsulting.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55187","6":"format-standard","7":"category-industry"},"yoast_head":"\nImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-25T13:03:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230325005002\/en\/1747133\/21\/download.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting\",\"datePublished\":\"2023-03-25T13:03:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/\"},\"wordCount\":267,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230325005002\\\/en\\\/1747133\\\/21\\\/download.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/\",\"name\":\"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230325005002\\\/en\\\/1747133\\\/21\\\/download.jpg\",\"datePublished\":\"2023-03-25T13:03:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230325005002\\\/en\\\/1747133\\\/21\\\/download.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230325005002\\\/en\\\/1747133\\\/21\\\/download.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting - Pharma Trend","og_description":"WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-25T13:03:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230325005002\/en\/1747133\/21\/download.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting","datePublished":"2023-03-25T13:03:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/"},"wordCount":267,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230325005002\/en\/1747133\/21\/download.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/","name":"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230325005002\/en\/1747133\/21\/download.jpg","datePublished":"2023-03-25T13:03:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230325005002\/en\/1747133\/21\/download.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230325005002\/en\/1747133\/21\/download.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/immunogen-presents-final-overall-survival-and-additional-efficacy-data-from-the-soraya-trial-at-sgo-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55187"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55187\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55187"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55187"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}